# New Triple Therapy in Newly Diagnosed Type 2 Diabetes

> **NCT06946628** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 296 (estimated)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Group A (triple combination therapy group)
- **DRUG:** Group B (standard therapy group)

## Key facts

- **NCT ID:** NCT06946628
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 296 (ESTIMATED)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06946628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06946628, "New Triple Therapy in Newly Diagnosed Type 2 Diabetes". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06946628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*